Messenger RNA technology offers a faster way to develop vaccines to address or prepare for pandemics, and Moderna’s vaccine candidate for avian influenza is on track for Phase 3 testing. But the Department of Health and Human Services has canceled a $590 million contract to support Moderna's pivotal trial.
The enduring legacy of the Ebola crisis serves as a poignant reminder of our shared responsibility in safeguarding public health and preventing future pandemics.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company.
BARDA is contributing funding for a Phase 3 clinical test of a Moderna messenger RNA vaccine that could protect against the strains of bird flu virus now spreading in U.S. dairy cows. The Moderna vaccine is currently in Phase 1/2 testing.
The WHO has released regulations on things to not include when naming new disease, such as reference to people, animals and places.